Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University18 enrolled

Overview

To determine the safety of Alimta when used with chemoradiation in inoperable non small cell lung cancer

To determine the maximal tolerated dose (MTD) and toxicities of Pemetrexed (Alimta) when administered concurrently with carboplatin and thoracic radiation therapy. To determine, qualitatively, the occurrence of local tumor responses identified with this regimen.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Inoperable Non Small Cell Lung Cancer

Interventions

Premetrexed (Alimta)DRUG

CarboplatinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Unresectable Stage II, IIIB or IV non small cell lung cancer. Evaluable disease on planning CT scan Zubrod 0-1 Weight loss equal to or less than 10% 3 months prior to diagnosis FEV1 greater than 1000cc Adequate hematologic, renal and hepatic functions Exclusion Criteria: * Small cell cancer Stage I non small cell cancer Prior chemotherapy or thoracic or lower neck radiatio therapy

Locations (1)

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Response and Progression Free Survival

Time frame: Up to five years after study completion

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.